🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchNNC0519-0396: Novo next-gen oral GLP-1 — anyone have experience?

NNC0519-0396: Novo next-gen oral GLP-1 — anyone have experience?

EndoResFellow Sat, Jan 3, 2026 at 11:36 AM 15 replies 968 viewsPage 1 of 3
EndoResFellow
Member
456
2,345
Sep 2024
Baltimore, MD
Jan 3, 2026 at 11:36 AM#1

Read the primary source rather than the write-up and the two do not agree, so here is what is actually in it.

The OASIS programme put 50mg oral in the same territory as 2.4mg injectable — around 15% mean weight loss — but it needed a dose 20 times larger to get there because almost none of the tablet is absorbed. The dose numbers are not comparable across routes and quoting them side by side confuses people.

Where I think it is weakest: the subgroup findings are the part I trust least — with enough subgroups something is always significant, and these were not all pre-registered.

The question I want answered is how much of the oral variability is the SNAC absorption window and how much is dose, because the two get conflated constantly. Practical detail welcome, however dull — the duller the better.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
3 6robert_kc, dan_philly, MeganSA_TX
Reply Quote Save Share Report
Dr.NateNeph
VIP Member
2,987
16,234
Dec 2023
Houston, TX
Jan 3, 2026 at 11:42 AM#2
EndoResFellow said:
The OASIS programme put 50mg oral in the same territory as 2.4mg injectable — around 15% mean weight loss — but it needed a dose 20 times larger to…

That is correct as far as it goes, and here is where it stops going. Oral semaglutide is absorbed in the stomach with the help of SNAC, which locally raises pH and protects the peptide long enough to cross. That mechanism is fragile: bioavailability is roughly 1% and highly sensitive to gastric contents, so a mouthful of coffee genuinely changes the exposure. This is why the label wants 30 minutes and no more than half a glass of plain water.

4 7NauseaFreeNow, SteveThurs, B12Beth and 1 other
Reply Quote Save Share Report
LabKate
Senior Member
2,678
11,234
Jan 2024
Oregon
Jan 3, 2026 at 11:48 AM#3
EndoResFellow said:
The OASIS programme put 50mg oral in the same territory as 2.4mg injectable — around 15% mean weight loss — but it needed a dose 20 times larger to…

I do not accept that the fasting window is a minor inconvenience. Adherence data on daily orals with timing requirements is consistently worse than weekly injections, and a drug you take imperfectly is a lower dose than the one on the box.

I would rather be corrected than agreed with, if it comes to it.

5 8Dr.SleepRoch, laura_annarbor, JenMemphis and 2 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
MASHdoc_SA
Member
456
2,345
Aug 2024
San Antonio, TX
Jan 3, 2026 at 11:54 AM#4

Short answer first, then the reasoning. Orforglipron is the more interesting oral story because it is not a peptide at all. Being a small molecule it does not need SNAC, does not need the fasting window, and has oral bioavailability in the tens of percent rather than about one.

Last edited: Jan 3, 2026 at 2:54 PM
6 9LabKate, kate.chem, DataDave and 3 others
Reply Quote Save Share Report
hyun_seoul
Member
345
1,456
Jul 2024
Seoul, KR
Jan 3, 2026 at 12:26 PM#5
Dr.NateNeph said:
Oral semaglutide is absorbed in the stomach with the help of SNAC, which locally raises pH and protects the peptide long enough to cross.

This is my experience too, for whatever a second data point is worth.

7 10LipidDoc_ATL, BariatricNurseD, MASHdoc_SA and 4 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register